Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
NINGBO INNO PHARMCHEM CO.,LTD. is a key supplier of advanced pharmaceutical compounds, including Cilengitide, a peptide with significant implications for treating challenging diseases like glioblastoma. This aggressive brain cancer presents unique therapeutic hurdles, and Cilengitide offers a promising avenue for overcoming them.
Glioblastoma is characterized by rapid growth, invasiveness, and a robust neovasculature that relies heavily on integrin signaling. Specifically, integrins αvβ3 and αvβ5 are often overexpressed in glioblastoma cells and the tumor's blood vessels. These integrins promote tumor cell migration, invasion into surrounding brain tissue, and the formation of abnormal, leaky blood vessels that contribute to tumor growth and resistance to treatment. This makes them prime targets for therapeutic intervention, driving interest in compounds like Cilengitide.
Cilengitide functions as a potent and selective inhibitor of these key integrins. By binding to αvβ3 and αvβ5, it disrupts the signaling pathways that support glioblastoma growth, invasion, and angiogenesis. Researchers are actively investigating cilengitide for glioblastoma treatment due to its ability to block these critical tumor-promoting activities. The compound's ability to be synthesized with high purity, as provided by NINGBO INNO PHARMCHEM CO.,LTD., is vital for accurate preclinical and clinical evaluation.
Clinical trials have explored Cilengitide's efficacy in patients with newly diagnosed and recurrent glioblastoma, often in combination with standard therapies such as radiation and chemotherapy. While results have been mixed, some studies have indicated potential benefits in certain patient subgroups. The ongoing research aims to refine treatment protocols and identify patient populations most likely to respond to Cilengitide-based therapies. The search for 'cilengitide clinical trials' reveals the extensive efforts in this area.
For researchers and pharmaceutical developers, access to reliable Cilengitide is essential. NINGBO INNO PHARMCHEM CO.,LTD. serves as a crucial supplier, ensuring the quality and consistency needed for such critical studies. The compound's unique mechanism of action as a selective integrin antagonist offers a targeted approach that could significantly improve treatment outcomes for glioblastoma patients.
In conclusion, Cilengitide represents a significant stride in the development of targeted therapies for glioblastoma. Its role in disrupting integrin-mediated processes fundamental to tumor progression highlights its therapeutic value. NINGBO INNO PHARMCHEM CO.,LTD. is proud to contribute to this vital research by providing high-quality Cilengitide.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
